1. Evaluation of atrial fibrillation management and cardiovascular risk profile in atrial fibrillation patients: A cross-sectional survey.
- Author
-
Račkauskas G, Zabiela V, Marinskis G, Baranauskas A, Balkutė D, Alunderytė J, Puodžiūkynas A, Kazakevičius T, Kviesulaitis V, and Aidietis A
- Subjects
- Aged, Aged, 80 and over, Anticoagulants administration & dosage, Comorbidity, Coronary Artery Disease drug therapy, Coronary Artery Disease epidemiology, Cross-Sectional Studies, Female, Fibrinolytic Agents administration & dosage, Heart Failure drug therapy, Heart Failure epidemiology, Hemorrhage drug therapy, Hemorrhage pathology, Hospitals, University, Humans, Hypertension drug therapy, Hypertension epidemiology, Lithuania epidemiology, Male, Middle Aged, Patient Compliance, Risk Factors, Surveys and Questionnaires, Anti-Arrhythmia Agents therapeutic use, Anticoagulants therapeutic use, Atrial Fibrillation drug therapy, Atrial Fibrillation epidemiology, Fibrinolytic Agents therapeutic use
- Abstract
Objective: The aim of this study to investigate the most frequent risk factors of atrial fibrillation (AF), co-morbidities, complications associated with AF and the use of anticoagulants and other medications in patients who were referred to university hospitals in Lithuania., Materials and Methods: This cross-sectional study enrolled consecutive inpatients and outpatients with AF presenting to cardiologists in the two biggest Lithuanian university hospitals from November 2013 to May 2014. AF diagnosis was confirmed by a 12-lead ECG or 24-h Holter with an episode duration of >30s., Results: A total number of 575 patients were recruited, and complete data on clinical subtype were available for 515 patients (mean age of 70.7 years; 48.5% of women). Permanent AF was the most frequent type of AF (46.6%). Common comorbidities were hypertension (85.8%), heart failure (77.9%) and coronary artery disease (51.8%). Amiodarone was the most common antiarrhythmic agent used in 14.6% of the patients, while beta-blockers and digoxin were the most often used rate control drugs (59.6% and 10.7%, respectively). Oral anticoagulants were used by 53.3% of the patients; of them, 95.6% used vitamin K antagonists, while non-vitamin K antagonist were used by only 4.4%. The INR within a therapeutic range (2.0-3.0) was documented in 19.2% of the patients. Other antithrombotic drugs such as aspirin and clopidogrel were used in 13.7% and 2.0% of the patients, respectively; dual antiplatelet treatment was administered in 6.2% of the patients. Of the entire cohort, the mean CHA
2 DS2 -VASc score was 3.97±1.6 and the mean HAS-BLED score was 2.25±1.0., Conclusions: Compliance with the treatment guidelines remains suboptimal and further patient education is needed., (Copyright © 2017 The Lithuanian University of Health Sciences. Production and hosting by Elsevier Sp. z o.o. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF